►增长 普冉股份业绩快报：2025年净利润2.08亿元 同比下降28.79% 铁科轨道业绩快报：2025年净利润1.71亿元 同比降20.09% 金冠电气业绩快报：2025年净利润8121.8万元 同比下降10.87% 上声电子业绩快报：2025年净利润1.84亿元，同比下降21.71% 康希诺业绩快报：2025年净利润2787.27万元，上年同期亏损3.79亿元 臻镭科技（维权）业绩快报：2025年净利润1.33亿元，同比增长582.01% 智明达业绩快报：2025年净利润1.1亿元，同比增长466.74% 三友医疗业绩快报：2025年净利润6328.95万元 同比增长451.85% 百奥赛图业绩快报：2025年净利润1.73亿元，同比增长416.37% 绿的谐波业绩快报：2025年净利润1.25亿元 同比增长122.4% 炬芯科技业绩快报：2025年净利润2.05亿元 同比增长91.95% 强一股份业绩快报：2025年净利润3.98亿元 同比增长70.73% 纳微科技业绩快报：2025年净利润1.36亿元 同比增长64.18% 中触媒业绩快报：2025年净利润2.12亿元，同比增长45.55% 泰福泵业业 ...

2月26日晚，华瓷股份(001216)发布公告称，公司于近日收到中国证监会出具的《关于同意湖南华联瓷 业股份有限公司向特定对象发行股票注册的批复》（证监许可[2026]309号），同意公司向特定对象发 行股票的注册申请。本次发行应严格按照报送深圳证券交易所的申报文件和发行方案实施。本批复自同 意注册之日起12个月内有效。 新诺威：拟2.3亿元转让国新汇金30%股份给石药控股 合合信息：2025年净利润同比增长13.39% 2月26日晚，合合信息(688615)发布业绩快报，2025年实现营业收入18.1亿元，同比增长25.83%；实现归 母净利润4.54亿元，同比增长13.39%；基本每股收益为3.24元/股。 生益科技：广新集团及陈仁喜已完成减持计划 2月26日晚，生益科技(600183)发布公告称，截至2026年2月25日，广新集团已通过集中竞价交易方式减 持公司股份合计2429.12万股，占公司总股本的1%。陈仁喜已通过集中竞价交易方式减持公司股份合计 30.08万股，占公司总股本的0.0124%。截至本公告披露日，广新集团及陈仁喜的减持计划已实施完毕。 华瓷股份：向特定对象发行股票申请获同意 2月26 ...

针对业绩变动的原因，澳华内镜表示，主要系业务收入增长有限，产品销售结构发生阶段性变化，综合 毛利率有所下滑，且上年同期财务数据比较基数较小，导致本期内相关比例波动较大。 北京商报讯（记者 丁宁）2月26日晚间，澳华内镜（688212）发布2025年业绩快报显示，公司2025年度 实现营业收入7.74亿元，同比增长3.2%；归属净利润1146.19万元，同比下滑45.45%。 ...

智通财经APP讯，澳华内镜(688212.SH)披露2025年度业绩快报，公司实现营业收入7.74亿元，同比增长 3.20%;实现归属于母公司所有者的净利润1146.19万元，同比减少45.45%;实现归属于母公司所有者的扣 除非经常性损益的净亏损711.48万元。 报告期内，公司海外市场准入及业务拓展成效显著，海外销售额实现较快增长，此外新一代旗舰机型 AQ400成功上市，进一步贡献业绩增量，多因素共振下，公司整体收入较上年同期实现小幅稳步增长; 同时，报告期内，公司产品销售结构发生阶段性变化，导致综合毛利率出现下滑，另一方面，公司为夯 实长期竞争力，持续加大市场营销体系建设、品牌影响力提升、产品迭代打磨及新技术研发的投入力 度，销售费用、管理费用、研发费用仍保持较高投入，导致业绩表现出现收入增长但利润下滑的情况。 ...

报告期内，公司海外市场准入及业务拓展成效显著，海外销售额实现较快增长，此外新一代旗舰机型 AQ400成功上市，进一步贡献业绩增量，多因素共振下，公司整体收入较上年同期实现小幅稳步增长； 同时，报告期内，公司产品销售结构发生阶段性变化，导致综合毛利率出现下滑，另一方面，公司为夯 实长期竞争力，持续加大市场营销体系建设、品牌影响力提升、产品迭代打磨及新技术研发的投入力 度，销售费用、管理费用、研发费用仍保持较高投入，导致业绩表现出现收入增长但利润下滑的情况。 格隆汇2月26日丨澳华内镜(688212.SH)公布2025年度业绩快报，报告期内，公司实现营业收入7.74亿 元，同比增长3.20%；实现归属于母公司所有者的净利润1146.19万元，同比减少45.45%；实现归属于母 公司所有者的扣除非经常性损益的净利润-711.48万元，同比略有下降。 报告期末，公司总资产20.11亿元，较报告期期初增长15.03%；归属于母公司的所有者权益13.13亿元， 较报告期期初减少3.90%。 ...

一、2025年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 77,353.71 | 74,954.95 | 3.20 | | 营业利润 | 116.17 | 704.37 | -83.51 | | 利润总额 | 10.68 | 642.63 | -98.34 | | 归属于母公司所有者的净利润 | 1,146.19 | 2,101.22 | -45.45 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | -711.48 | -628.62 | 不适用 | | 基本每股收益（元） | 0.09 | 0.16 | -43.75 | | 加权平均净资产收益率 | 0.89% | 1.53% | 减少 0.64 个百分点 | | | 本报告期末 | 本报告期初 | 增减变动幅度（％） | | 总资产 | 201,142.64 | 174,867.66 | 15.03 | | 归属于母公司的所有者权益 | 131,282.82 | 136,605.57 | -3.90 | | 股 ...

澳华内镜公告称，2025年公司实现营业收入77,353.71万元，同比增长3.20%；归属于母公司所有者的净 利润1,146.19万元，同比减少45.45%；扣非净利润-711.48万元，同比略有下降。报告期末，总资产 201,142.64万元，较期初增长15.03%；归属于母公司的所有者权益131,282.82万元，较期初减少3.90%。 业绩变动因产品销售结构变化致毛利率下滑，且营销、研发等费用投入高。数据为初步核算，以年报为 准。 ...

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, attracting attention due to its impressive financial metrics and leading position in the disposable endoscope market, while also facing challenges such as high customer concentration, declining cash flow, and increasing market competition [1][3]. Financial Performance - The company reported a gross margin of 72.62% and a net margin of 47.26% for 2024, with a significant increase in gross margin from 69.1% in 2023 to 73.7% in the first nine months of 2025, indicating strong profitability driven by vertical integration [2][4]. - Revenue for 2024 is projected at 1.41 billion RMB, a 4.4% increase from 1.35 billion RMB in 2023, while revenue growth slowed to 3.86% in the first nine months of 2025 compared to the same period in 2024 [3][4]. - Taxable profit reached 81.83 million RMB in 2024, a 28.0% increase from 63.92 million RMB in 2023, but fell by 16.2% to 58.93 million RMB in the first nine months of 2025 [4][6]. Market Position - Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, showcasing its international competitiveness in a highly regulated environment [3][9]. - The disposable endoscope market is expected to grow from approximately 2 billion USD in 2023 to over 6 billion USD by 2030, with a compound annual growth rate exceeding 17% [8][9]. Competitive Landscape - The market is dominated by major players such as Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, presenting significant competitive challenges for Mingzhi Technology [9][10]. - The company faces increasing pressure from local competitors in China, such as Kaili Medical, which has entered the disposable ureteroscope segment, intensifying competition [9][10]. Operational Challenges - Customer concentration remains high, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10][11]. - The company relies heavily on distributors for revenue, with 92.8% of income coming from this channel in 2024, which may limit direct customer engagement and profit margins [10][11]. - Cash flow has deteriorated, with operating cash flow declining by 19.45% in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11][12]. Strategic Outlook - Mingzhi Technology's financial and operational indicators suggest it is at a critical juncture, needing to balance high profitability with sustainable growth strategies amid intensifying competition [7][11]. - The ability to manage operational and financial risks while leveraging technological innovation and maintaining supply chain efficiency will be crucial for the company's long-term value creation [12].

Group 1: Company Overview - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International as the sole sponsor [1] - The company specializes in disposable endoscopes and has gained significant attention in the capital market due to its impressive financial metrics, including a gross margin of 72.62% and a net margin of 47.26% for 2024 [1] - Despite its high profitability, the company faces challenges such as high customer concentration, declining cash flow, and increasing market competition [1] Group 2: Business Model and Competitive Advantage - Mingzhi Technology positions itself as a "platform medical device company" with a unique vertical integration model, controlling the entire supply chain from core optical components to system assembly [2] - This vertical integration has resulted in significant cost advantages and technical control, with gross margins increasing from 69.1% in 2023 to 73.7% in the first nine months of 2025 [2][4] - The company has developed competitive products, including some of the thinnest disposable ureteroscopes and cystoscopes, which are crucial for minimally invasive surgeries [2] Group 3: Market Position and Financial Performance - By 2024, Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, reflecting its international competitiveness [3] - The company's revenue for 2024 is projected to be 141.05 million RMB, a 4.4% increase from 2023, but growth has shown signs of slowing down, with only a 3.86% increase in the first nine months of 2025 [3][4] - The gross profit margin has shown a consistent upward trend, but net profit has declined by 14.5% in the first nine months of 2025 compared to the same period in 2024, indicating emerging challenges in profitability [4][11] Group 4: Industry Dynamics and Challenges - The disposable endoscope market is experiencing rapid growth, with projections indicating an expansion from approximately $2 billion in 2023 to over $6 billion by 2030, reflecting a compound annual growth rate of over 17% [8][9] - However, the market is dominated by major players like Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, creating significant competitive barriers [9] - Mingzhi Technology's revenue is heavily reliant on overseas markets, exposing it to risks from geopolitical issues, currency fluctuations, and changes in international trade policies [10] Group 5: Operational Risks and Financial Health - The company has a high customer concentration, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10] - The sales channel structure is heavily reliant on distributors, with 92.8% of revenue coming from this channel in 2024, which may limit direct customer engagement and profit margins [10] - Operational efficiency is under pressure, as evidenced by a 19.45% decline in operating cash flow in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11]